JP2011501951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501951A5 JP2011501951A5 JP2010531076A JP2010531076A JP2011501951A5 JP 2011501951 A5 JP2011501951 A5 JP 2011501951A5 JP 2010531076 A JP2010531076 A JP 2010531076A JP 2010531076 A JP2010531076 A JP 2010531076A JP 2011501951 A5 JP2011501951 A5 JP 2011501951A5
- Authority
- JP
- Japan
- Prior art keywords
- scaffold
- chain
- seq
- loop
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims 15
- 229940024606 amino acid Drugs 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000019040 Nuclear Antigens Human genes 0.000 claims 1
- 108010051791 Nuclear Antigens Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98420907P | 2007-10-31 | 2007-10-31 | |
| PCT/US2008/012398 WO2009058379A2 (en) | 2007-10-31 | 2008-10-31 | Protein scaffolds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243591A Division JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501951A JP2011501951A (ja) | 2011-01-20 |
| JP2011501951A5 true JP2011501951A5 (cg-RX-API-DMAC7.html) | 2011-12-22 |
Family
ID=40591700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531076A Pending JP2011501951A (ja) | 2007-10-31 | 2008-10-31 | タンパク質足場 |
| JP2014243591A Active JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243591A Active JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8633297B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2215246B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2011501951A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101686247B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101932720A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008319298B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0818810A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2704229C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2533874T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010004374A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010121967A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009058379A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| MX2010004374A (es) | 2007-10-31 | 2010-04-30 | Medimmune Llc | Armazones proteinicos. |
| CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| WO2010051274A2 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| AU2010226726B8 (en) | 2009-03-16 | 2014-08-14 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| ES2755398T3 (es) * | 2010-04-13 | 2020-04-22 | Medimmune Llc | Andamios multiméricos específicos de TRAIL R2 |
| AU2011245225B2 (en) * | 2010-04-30 | 2015-09-17 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| EP2672995B1 (en) * | 2011-02-11 | 2019-01-02 | Research Corporation Technologies, Inc. | Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
| SMT201700025T1 (it) | 2011-04-13 | 2017-03-08 | Bristol Myers Squibb Co | Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| KR102035713B1 (ko) | 2011-09-27 | 2019-10-24 | 얀센 바이오테크 인코포레이티드 | 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드 |
| DK2771022T3 (da) * | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| AU2012338733B2 (en) * | 2011-11-16 | 2017-08-24 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| NZ624873A (en) * | 2011-11-16 | 2016-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| EP2780371B1 (en) * | 2011-11-16 | 2018-10-24 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| JP6346895B2 (ja) | 2012-09-13 | 2018-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質 |
| WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| WO2014124017A1 (en) | 2013-02-06 | 2014-08-14 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| ES2813501T3 (es) | 2013-02-12 | 2021-03-24 | Bristol Myers Squibb Co | Métodos de replegado de proteínas basados en filtración de flujo tangencial |
| EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| DK2970473T3 (da) | 2013-03-14 | 2017-11-27 | Bristol Myers Squibb Co | Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf |
| DK2970921T3 (en) | 2013-03-15 | 2019-01-14 | Atyr Pharma Inc | Histidyl-tRNA synthetase-Fc conjugates |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| JP6644701B2 (ja) | 2014-03-20 | 2020-02-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 安定化したフィブロネクチンベーススキャフォールド分子 |
| EA034886B1 (ru) | 2014-03-20 | 2020-04-02 | Бристол-Майерс Сквибб Компани | Связывающие сывороточный альбумин домены фибронектина iii типа |
| CN106573961B (zh) * | 2014-06-20 | 2022-01-04 | 豪夫迈·罗氏有限公司 | 基于chagasin的支架组合物、方法和应用 |
| RU2715905C2 (ru) | 2014-10-01 | 2020-03-04 | МЕДИММЬЮН, ЭлЭлСи | Способ конъюгации полипептида |
| US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| EP3223866B1 (en) | 2014-11-25 | 2023-03-08 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| JP6893504B2 (ja) | 2015-09-23 | 2021-06-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン |
| JP6907199B2 (ja) * | 2015-10-30 | 2021-07-21 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｄ−タンパク質リガンドの構造ベース設計 |
| ES3013312T3 (en) | 2015-12-17 | 2025-04-11 | Univ Johns Hopkins | Ameliorating systemic sclerosis with death receptor agonists |
| US11084879B2 (en) | 2016-04-07 | 2021-08-10 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| TW201825118A (zh) * | 2016-11-30 | 2018-07-16 | 美商艾堤爾製藥公司 | 抗-hrs抗體及用於治療癌症之組合療法 |
| EP3932432A1 (en) | 2016-12-14 | 2022-01-05 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
| WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| EP3618845B1 (en) * | 2017-05-04 | 2021-01-13 | Follicum AB | Peptides for treatment of diabetes |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| US11680091B2 (en) | 2018-02-23 | 2023-06-20 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type III (FN3) monobodies |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| WO2021009692A1 (en) | 2019-07-15 | 2021-01-21 | Medimmune Limited | Tripartite systems for protein dimerization and methods of use |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| CN116568341A (zh) | 2020-02-28 | 2023-08-08 | 百时美施贵宝公司 | 基于纤连蛋白的放射性标记的支架和抗体及其治疗诊断用途 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| US11566346B2 (en) * | 2020-06-25 | 2023-01-31 | Philip David Rodley | Protein scaffold |
| IL307595A (en) | 2021-04-14 | 2023-12-01 | Aro Biotherapeutics Company | FN3 RNA-silencing region conjugates and their uses |
| WO2022221505A2 (en) | 2021-04-14 | 2022-10-20 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024261323A1 (en) | 2023-06-23 | 2024-12-26 | Astrazeneca Ab | Molecular switches |
| WO2025125630A1 (en) | 2023-12-15 | 2025-06-19 | Medimmune Limited | Method for bioprotac design |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5618709A (en) | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
| WO1996008513A1 (en) * | 1994-09-16 | 1996-03-21 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same |
| US5998596A (en) | 1995-04-04 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of protein kinase activity by aptameric action of oligonucleotides |
| WO1996038176A1 (fr) | 1995-06-01 | 1996-12-05 | Kishimoto, Tadamitsu | Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1) |
| GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
| US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| BR9610745A (pt) | 1995-12-08 | 1999-07-13 | Janssen Pharmaceutica Nv | Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil |
| AU703203B2 (en) | 1996-01-30 | 1999-03-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997027854A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
| EP0907649A1 (en) | 1996-06-27 | 1999-04-14 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
| US6040305A (en) | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5945429A (en) | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
| US6093737A (en) | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6013662A (en) | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ZA981080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
| TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| US6051582A (en) | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6225322B1 (en) | 1997-06-17 | 2001-05-01 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6159984A (en) | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ATE205195T1 (de) | 1997-10-22 | 2001-09-15 | Astrazeneca Ab | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren |
| US6124465A (en) | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| EP1045846B1 (en) | 1997-11-28 | 2003-05-02 | Lg Chemical Limited | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| US6054466A (en) | 1997-12-04 | 2000-04-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DK1076663T3 (da) | 1998-04-27 | 2004-06-01 | Warner Lambert Co | Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer |
| AU731758B2 (en) | 1998-07-08 | 2001-04-05 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6372747B1 (en) | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6362188B1 (en) | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
| FR2787327B1 (fr) | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| US6143766A (en) | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
| CA2416219C (en) * | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| WO2003083125A1 (en) * | 2002-03-29 | 2003-10-09 | Genencor International, Inc. | Ehanced protein expression in bacillus |
| AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
| CA2489348A1 (en) * | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| US7175895B2 (en) * | 2003-11-19 | 2007-02-13 | Kimberly-Clark Worldwide, Inc. | Glove with medicated porous beads |
| BRPI0417302A (pt) * | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| KR100852415B1 (ko) * | 2004-07-13 | 2008-08-18 | 재단법인서울대학교산학협력재단 | 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체 |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| JP4959226B2 (ja) | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| JP5781762B2 (ja) * | 2007-08-10 | 2015-09-24 | プロテリックス、インク | ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ |
| MX2010004374A (es) | 2007-10-31 | 2010-04-30 | Medimmune Llc | Armazones proteinicos. |
| KR20100111283A (ko) | 2007-12-27 | 2010-10-14 | 노파르티스 아게 | 개선된 피브로넥틴계 결합 분자 및 그들의 용도 |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| WO2010051274A2 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
-
2008
- 2008-10-31 MX MX2010004374A patent/MX2010004374A/es active IP Right Grant
- 2008-10-31 AU AU2008319298A patent/AU2008319298B2/en active Active
- 2008-10-31 BR BRPI0818810-6A2A patent/BRPI0818810A2/pt not_active Application Discontinuation
- 2008-10-31 KR KR1020107011856A patent/KR101686247B1/ko active Active
- 2008-10-31 CN CN2008801146605A patent/CN101932720A/zh active Pending
- 2008-10-31 WO PCT/US2008/012398 patent/WO2009058379A2/en not_active Ceased
- 2008-10-31 US US12/739,149 patent/US8633297B2/en active Active
- 2008-10-31 CA CA2704229A patent/CA2704229C/en active Active
- 2008-10-31 JP JP2010531076A patent/JP2011501951A/ja active Pending
- 2008-10-31 EP EP08845766.8A patent/EP2215246B1/en active Active
- 2008-10-31 RU RU2010121967/10A patent/RU2010121967A/ru not_active Application Discontinuation
- 2008-10-31 ES ES08845766.8T patent/ES2533874T3/es active Active
-
2013
- 2013-12-13 US US14/106,689 patent/US9176129B2/en active Active
-
2014
- 2014-12-02 JP JP2014243591A patent/JP6034846B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501951A5 (cg-RX-API-DMAC7.html) | ||
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| AU2014301777B2 (en) | High-stability T-cell receptor and preparation method and application thereof | |
| DK2681245T3 (en) | MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS | |
| CN103180339B (zh) | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 | |
| AU2017273743B2 (en) | Serum albumin-binding fibronectin type III domains | |
| JP2020511949A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512213A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527272A5 (cg-RX-API-DMAC7.html) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| JP2013529070A5 (cg-RX-API-DMAC7.html) | ||
| RU2010121967A (ru) | Белковые каркасные структуры | |
| JP2017536098A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516049A5 (cg-RX-API-DMAC7.html) | ||
| WO2009142773A4 (en) | Multivalent fibronectin based scaffold domain proteins | |
| DK2190863T3 (en) | New albumin binding compositions, methods and uses | |
| JP2015509707A5 (cg-RX-API-DMAC7.html) | ||
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| IL292358A (en) | specific binding molecules | |
| Lindgren et al. | A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life | |
| WO2024084203A1 (en) | Single domain antibodies binding to albumin | |
| JP2019511457A5 (cg-RX-API-DMAC7.html) | ||
| CN115803339A (zh) | 特异性结合分子 | |
| JP7594542B2 (ja) | Ｈｂｖエンベロープタンパク質に特異的な結合性分子 | |
| CA3250782A1 (en) | HIV-SPECIFIC BINDING MOLECULES AND TCR |